Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, SARS-CoV-2 and COVID-19 Research, and Virus-based gene therapy research.
Inhibition of placental trophoblast fusion by guanylate-binding protein 5.
HIV-1 and BLV are insensitive to SERINC5 restriction under the cell-cell infection.
Further Characterization of the Antiviral Transmembrane Protein MARCH8.
Membrane-Associated Ubiquitin Ligase RING Finger Protein 152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination.
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to <i>Rhinolophus</i> bat ACE2.
Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.
Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination
Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination
Membrane-Associated Ubiquitin Ligase RNF152 Orchestrates Melanogenesis via Tyrosinase Ubiquitination
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins
MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins.
MARCH8: the tie that binds to viruses.
Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon.
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
MARCH8: the tie that binds to viruses
SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity
Phenotypic and Genotypic Co-receptor Tropism Testing in HIV-1 Epidemic Region of Tanzania Where Multiple Non-B Subtypes Co-circulate.
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses.
MARCH8 targets cytoplasmic lysine residues of various viral envelope glycoproteins
Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag.